Intranasal immunization with pneumococcal surface protein A in the presence of nanoparticle forming polysorbitol transporter adjuvant induces protective immunity against the Streptococcus pneumoniae infection. (May 2019)

• Record Type: Journal Article
• Authors: Kye, Yoon-Chul; Park, Sung-Moo; Shim, Byoung-Shik; Firdous, Jannatul; Kim, Girak; Kim, Han Wool; Ju, Young-Jun; Kim, Cheol Gyun; Cho, Chong-Su; Kim, Dong Wook; Cho, Jae Ho; Song, Man Ki; Han, Seung Hyun; Yun, Cheol-Heui
• Is Part Of: Acta biomaterialia. Volume 90(2019)
• Page Start: 362
• Page End: 372
• Publication Date: 2019-05
• Subjects: Vaccine adjuvant -- Polysorbitol transporter -- Streptococcus pneumoniae -- Pneumococcal surface protein A -- Nanoparticle -- Dendritic cells; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1016/j.actbio.2019.03.049
• Languages: English
• ISSNs: 1742-7061

Abstract

Graphical abstract: Abstract: Developing effective mucosal subunit vaccine for the Streptococcus pneumoniae has been unsuccessful mainly because of their poor immunogenicity with insufficient memory T and B cell responses. We thus address whether such limitation can be overcome by introducing effective adjuvants that can enhance immunity and show here that polysorbitol transporter (PST) serves as a mucosal adjuvant for a subunit vaccine against the Streptococcus pneumoniae . Pneumococcal surface protein A (PspA) with PST adjuvant induced protective immunity against S. pneumoniae challenge, especially long-term T and B cell immune responses. Moreover, we found that the PST preferentially induced T helper (Th) responses toward Th2 or T follicular helper (Tfh) cells and, importantly, that the responses were mediated through antigen-presenting cells via activating a peroxisome proliferator-activated receptor gamma (PPAR-γ) pathway. Thus, these data indicate that PST can be used as an effective and safe mucosal vaccine adjuvant against S. pneumoniae infection. State of Significance: In this study, we suggested the nanoparticle forming adjuvant, PST works as an effective adjuvant for the pneumococcal vaccine, PspA. The PspA subunit vaccine together with PST adjuvant efficiently induced protective immunity, even in the long-term memory responses, against Streptococcus pneumoniae lethal challenge. We found that PspA with PST adjuvant induced dendritic cell activation followed by follicular helper T cell responses through PPAR-γ pathway resulting long-term memory antibody-producing cells. Consequently, in this paper, we suggest the mechanism for safe nanoparticle forming subunit vaccine adjuvant against pneumococcal infection.